Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster III

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1853

A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease

1:00PM-3:00PM: Abstract Number: 1839

Appendicitis Still a Challenge for FMF Patients?

1:00PM-3:00PM: Abstract Number: 1844

Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital

1:00PM-3:00PM: Abstract Number: 1834

Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study

1:00PM-3:00PM: Abstract Number: 1846

Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease

1:00PM-3:00PM: Abstract Number: 1830

Characteristics of Arthritis in Familial Mediterranean Fever Patients

1:00PM-3:00PM: Abstract Number: 1849

Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center

1:00PM-3:00PM: Abstract Number: 1848

Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope

1:00PM-3:00PM: Abstract Number: 1852

Clinical Efficacy and Safety of Guselkumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 48 Analyses from the Phase 2 GALAXI 1 Study

1:00PM-3:00PM: Abstract Number: 1835

Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1855

Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy

1:00PM-3:00PM: Abstract Number: 1847

Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)

1:00PM-3:00PM: Abstract Number: 1837

Eales Disease and Vogt-Koyanagi-Harada Syndrome: Not Everything Is Anterior Uveitis in Rheumatology

1:00PM-3:00PM: Abstract Number: 1832

Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study

1:00PM-3:00PM: Abstract Number: 1831

Establishing a Scientific Bridge to Historic VIOXX to Enable a Reintroduction of Rofecoxib: Pharmacokinetic Evaluation of TRM‑201 (Rofecoxib)

1:00PM-3:00PM: Abstract Number: 1850

Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2

1:00PM-3:00PM: Abstract Number: 1833

Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial

1:00PM-3:00PM: Abstract Number: 1845

Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study

1:00PM-3:00PM: Abstract Number: 1854

Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions

1:00PM-3:00PM: Abstract Number: 1851

Phenotype and Genotype of Adult-onset Adenosine Deaminase 2 Deficiency Patients

1:00PM-3:00PM: Abstract Number: 1838

Real-World Treatment Patterns Among Adult Patients with Dermatomyositis in the United States

1:00PM-3:00PM: Abstract Number: 1836

Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis

1:00PM-3:00PM: Abstract Number: 1840

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort

1:00PM-3:00PM: Abstract Number: 1841

To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis

1:00PM-3:00PM: Abstract Number: 1843

Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience

1:00PM-3:00PM: Abstract Number: 1842

Vaccination in Patients with Autoinflammatory Periodic Syndromes Under Canakinumab – Safety Data Interim Analysis of the RELIANCE Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].